atai Life Sciences (ATAI) IPO Prices at $15

atai Life Sciences B.V. (Nasdaq: ATAI) announced the pricing of its upsized initial public offering in the United States of 15,000,000 common shares at a price to the public of $15.00 per share. All common shares are being offered by atai.

Credit Suisse, Citigroup, Cowen, and Berenberg are acting as book-running managers for the proposed offering. Cantor, RBC Capital Markets and Canaccord Genuity are also acting as book-running managers for the proposed offering.

atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooked or underused, including psychedelic compounds and digital therapeutics. atai is headquartered in Berlin, with offices in New York and London.

You May Also Be Interested In

• Citigroup set to join top banks in Anthropic IPO - Bloomberg
• Citi upgrades O-I Glass to Buy with $9 price target, opens 90-Day upside catalyst watch
• Robotics boom fueling nation's tech ambitions